Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery
Status:
Completed
Trial end date:
2016-04-02
Target enrollment:
Participant gender:
Summary
Patients who had at least two risk factors of PONV (Postoperative nausea and vomiting) and
underwent laparoscopic surgeries under general anesthesia were assessed for eligibility.
Patients who developed PONV within the first 2 hours after anesthesia received intravenously,
in a randomized double-blind manner, ondansetron 4 mg or ramosetron 0.3 mg. Patients were
then observed for 24 hours after drug administration. The incidence of nausea and vomiting,
severity of nausea, requirements for rescue antiemetic and adverse effects at 0-2 and 2-24
hours after drug administration were evaluated. The primary endpoint was the rate of patients
exhibiting complete response, defined as no emesis and no further rescue antiemetic
medication for 24 hours after drug administration.